The influence of statins on the free intracellular calcium concentration in human umbilical vein endothelial cells

被引：6

作者：

Heinke S. ^{[1
]}

Schwarz G. ^{[1
]}

Figulla H.R. ^{[1
]}

Heinemann S.H. ^{[2
]}

机构：

[1] Clinics for Internal Medicine I Med., Fac. of the Friedrich Schiller Univ., D-07747 Jena

[2] Unit Molec./Cellular Biophys. Med., Fac. of the Friedrich Schiller Univ., D-07747 Jena

来源：

BMC Cardiovascular Disorders | / 4卷 / 1期

关键词：

Arteriosclerosis; Endothelium; Free intracellular calcium; Hydroxymethylglutaryl CoA reductase inhibitors; Nitric oxide;

D O I：

10.1186/1471-2261-4-4

中图分类号：

学科分类号：

摘要：

Background: Statins are cholesterol-lowering drugs that are widely used to reduce the risk of cardiac infarction. Their beneficial clinical effects, however, are not restricted to their influence on cholesterol production. As several studies have shown that they have a potency of relaxing blood vessels. Methods: We measured the effects of statins on the intracellular free calcium concentration ([Ca2+]i) in human umbilical vein endothelial cells (HUVEC) after acute application and 24-hpreincubation of statins. Results: Incubation of the cells for 24 h with cerivastatin or fluvastatin significantly increased the resting [Ca2+]i. For cerivastatin this effect manifested at a concentration of 1 μM. Increase of resting [Ca2+]i in the presence of cerivastatin also occurred when the nitric oxide synthase was inhibited. Transient Ca2+ release induced by histamine was not affected. Conclusions: The increase of resting [Ca2+]i after incubation with cerivastatin or fluvastatin may provide an explanation for the direct effects of statins on the endothelial-dependent vasodilatation and restoration of endothelial activity in vivo. © 2004 Heinke et al; licensee BioMed Central Ltd.

引用

页数：6

共 19 条

[1]

Alvarez de Sotomayor M., Herrera M.D., Marhuenda E., Andriantsitohaina R., Characterization of endothelial factors involved in the vasodilatory effect of simvastatin in aorta and small mesenteric artery of the rat, Br. J. Pharmacol., 131, pp. 1179-1187, (2000)

[2]

Boer R., Ulrich W.R., Klein T., Mirau B., Haas S., Baur I., The inhibitory potency and selectivity of arginine substrate site nitric-oxide synthase inhibitors is solely determined by their affinity toward the different isoenzymes, Mol. Pharmacol., 58, 5, pp. 1026-1034, (2000)

[3]

Endres M., Laufs U., Huang Z., Nakamura T., Huang P., Moskowitz M.A., Liao J.K., Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase, Proc. Natl. Acad. Sci. USA, 95, pp. 8880-8885, (1998)

[4]

Fleming I., Busse R., Signal transduction of eNOS activation, Cardiovasc. Res., 43, pp. 532-541, (1999)

[5]

Govers R., Rabelink T.J., Cellular regulation of endothelial nitric oxide synthase, Am. J. Physiol. Renal. Physiol., 280, (2001)

[6]

Grynkiewicz G., Poenie M., Tsien R.Y., A new generation of Ca<sup>2+</sup> indicators with greatly improved fluorescence properties, J. Biol. Chem., 260, pp. 3440-3450, (1985)

[7]

Hernandez-Perera O., Perez-Sala D., Navarro-Antolin J., Sanchez-Pascuala R., Hernandez G., Diaz C., Lamas S., Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells, J. Clin. Invest., 101, pp. 2711-2719, (1998)

[8]

Kaesemeyer W.H., Caldwell R.B., Huang J., Caldwell R.W., Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions, Am. Coll. Cardiol., 33, pp. 234-241, (1999)

[9]

Laufs U., la Fata V., Plutzky J., Liao J.K., Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors, Circulation, 97, pp. 1129-1135, (1998)

[10]

Laufs U., Liao J.K., Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase, J. Biol. Chem., 273, pp. 24266-24271, (1998)

← 1 2 →